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Natural flavonoids with methoxy substitutions are metabolized by CYP1 enzymes to 
yield the corresponding demethylated products. The present study aimed to 
characterize the metabolism and further antiproliferative activity of the hydroxylated 
flavonoids apigenin, luteolin, scutellarein, kaempferol and quercetin in CYP1 
recombinant enzymes and in the CYP1 expressing cell lines MCF7 and MDA–MB–
468, respectively. Apigenin was converted to luteolin and scutellarein, whereas 
kaempferol was metabolized only to quercetin by recombinant CYP1 enzymes. 
Luteolin metabolism yielded 6 hydroxyluteolin only by recombinant CYP1B1, 
whereas CYP1A1 and CYP1A2 were not capable of metabolizing this compound. 
Molecular modeling demonstrated that CYP1B1 favored the A ring orientation of 
apigenin and luteolin to the heme group compared with CYP1A1. The IC50 of the 
compounds luteolin, scutellarein and 6 hydroxyluteolin was significantly lower in 
MDA–MB–468, MCF7 and MCF10A cells compared with that of apigenin. Similarly, 
the IC50 of quercetin in MDA–MB–468 cells was significantly lower compared with 
that of kaempferol. The most potent compound was luteolin in MDA–MB–468 cells 
(IC50= 2±0.3 μM). In the presence of the CYP1-inhibitors α-napthoflavone and/or 
acacetin, luteolin activation was lessened. Taken collectively, the data demonstrate 
that the metabolism of hydroxylated flavonoids by cytochrome P450 CYP1 enzymes, 
notably CYP1A1 and CYP1B1, can enhance their antiproliferative activity in breast 
cancer cells. In addition, this antiproliferative activity is attributed to the combined 
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Breast cancer is one of the major causes of cancer–related deaths accounting for 
540,000 deaths each year worldwide (Lopes et al., 2017). The treatment options for 
breast cancer include surgery, radiotherapy, hormone therapy and chemotherapy. A 
major obstacle that is encountered with conventional breast cancer therapy is the 
recurrence of the tumor progression. In addition, the use of certain chemotherapeutic 
drugs, notably the alkylating agent carboplatin, the antimetabolite 5–fluorouracil and 
the antimitotic agents paclitaxel and docetaxel, confers limited specificity for the 
tumor site and consequently severe side effects to the healthy tissue. Hence, in the 
past two decades considerable effort has been made to the research and development 
of new drugs with enhanced specificity and improved efficacy for the treatment of 
breast cancer. In addition, the use of complementary medical treatment namely, 
phytotherapeutic natural products and nutritional supplements, for women with a 
previous history of breast cancer has considerably increased (Lopes et al., 2017; 
Margină, et al., Fenga et al., 2016). 
Flavonoids comprise a class of natural polyphenolic molecules that have 
demonstrated a major role in the prevention of cancer. These compounds are 
ubiquitous in plant–based food products, such as fruits, vegetables and tea extracts 
and in medicinal plants. Their anticancer activity has been attributed to the inhibition 
of DNA damage, the inhibition of cell cycle associated proteins, the induction of 
apoptosis, the modulation of cell signaling pathways involved in proliferation and in 
the inhibition of carcinogenic metabolite formation (George et al., 2017; Curti et al., 
2017; Kerimi et al., 2017; Clementino et al., 2017). The hydroxylated flavonoids 
apigenin, luteolin, quercetin and kaempferol are the main constituents of various 
dietary products and beverages and have been the focus of extensive research over the 
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last years. Apigenin exerts anticancer effects through the modulation of various 
pathways namely, apoptosis, ROS and DNA damage and repair (Salmani et al., 2017). 
Luteolin is a flavone that differs from apigenin by a single hydroxyl group at the 3´ 
position of the B ring. This compound is found in various common dietary sources 
notably artichoke, chamomile and olive oil (Garcia–Gonzalez et al. 2010; Kato et al., 
2008; Pandino et al., 2010). Luteolin has demonstrated anticancer activity in cancer 
cell lines and in vivo models (Seelinger et al., 2008). This type of activity has been 
attributed to activation of apoptosis, cell cycle arrest and inhibition of tumor invasion 
(Seelinger et al., 2008). Moreover, quercetin that contains an extra hydroxyl group at 
the 3 position of the C ring compared with luteolin, has been examined as a putative 
anticancer agent in ovarian and melanoma cancers via similar modes of action 
(Parvaresh et al., 2016; Harris et al., 2016) 
The metabolism of xenobiotics is facilitated by specific phase–I and phase–II drug 
metabolizing enzymes (Tsatsakis et al., 2009; Tsatsakis et al., 2011). Previous studies 
conducted by our group have demonstrated that methoxylated flavonoids, such as 
diosmetin and eupatorin, are demethylated to their corresponding hydroxylated 
derivatives by recombinant cytochrome P450 CYP1A1, CYP1B1 and CYP1A2 
enzymes and by MCF7 and MDA–MB–468 breast adenocarcinoma cellular extracts 
(Androutsopoulos et al., 2008; Androutsopoulos et al., 2009a). The cytochrome P450 
enzymes CYP1A1 and CYP1B1 have been implicated in carcinogenesis and their 
upregulation in cancer cells has been used for the development of novel 
chemotherapeutic drugs (Patterson and Murray 2002; Gribben et al., 2005). 
Extrahepatic CYPs, notably CYP1B1 and CYP1A1, may be utilized to target tumor 
cells by the use of selective antibodies, or the activation of prodrugs that are inactive 
in tissues or cells that do not express these enzymes (Gribben et al., 2005; Loaiza–
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Pérez et al., 2004). Our previous reports suggest that several dietary flavonoids are 
substrates for CYP1 enzymes and may exhibit cancer–therapeutic applications, 
provided their conversion products inhibit tumor cell growth (Androutsopoulos et al., 
2010).  
In the present study, the CYP1–mediated metabolism of hydroxylated flavonoids 
namely, apigenin, luteolin, quercetin and kaempferol was investigated in recombinant 
CYP1 enzymes. In addition, their antiproliferative activity was assessed in the CYP1 
expressing cell lines MCF7 and MDA–MB–468. The data demonstrate that 
bioactivation of hydroxylated dietary flavonoids by CYP1 enzymes is possible and 
that the number of hydroxyl groups affects the inhibition of cellular proliferation in 
breast cancer cells.  
 
2. Materials and Methods 
2.1 Chemicals and antibodies 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), propidium 
iodide (PI), α-napthoflavone, acacetin, apigenin, luteolin, kaempferol, quercetin, 
tissue culture reagents and media, Western blotting lysis buffer and DTT were 
purchased from Sigma Aldrich (St Louis, MO, USA). Scutellarein was purchased 
from Extrasynthese (Lyon, France) and 6-OH luteolin was synthesized as described in 
previous methodologies (Androutsopoulos et al., 2009c). Western blotting reagents 
were from Bio-rad (Berkeley, CA, USA). The polyclonal antibody for CYP1B1 was 
from Gentest (BD Biosciences, CA, USA), whereas the monoclonal for β-actin from 
Cell signaling (Leiden, Netherlands). Secondary antibodies for western blotting were 
from Santa Cruz Biotechnology (Dallas, TX, USA).  
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2.2 Cell culture  
MCF7 and MDA–MB–468 cells were maintained in RPMI with glutamine (2 mM) 
containing 10% heat-inactivated FBS and penicillin/streptomycin. MDA–MB–468 
cells were grown in RPMI without phenol red, whereas the growth medium of 
MCF10A cells included DMEM:F12 with insulin (10 μg/ml), hydrocortisone (500 
ng/ml) EGF (20 ng/ml), in addition to 10% FBS and 2 mM of glutamine. The cells 
were grown in a humidified incubator at 37 C in 5% CO2 /95% air and passaged 
using trypsin EDTA (0.25% v/v), every 3 to 4 days.  
 
2.3 Flavonoid metabolism  
Recombinant CYP1 enzymes and control microsomes that were purchased from 
Gentest (BD Biosciences, CA, USA) were incubated with 10 μM of flavonoids 
(apigenin, luteolin, kaempferol and quercetin). The reactions were carried out at 37 °C 
in a humidified incubator in the presence of NADPH (0.5 mM), MgCl2 (0.5 mM) and 
phosphate buffer (20 mM). Time points were obtained at 0, 5, 10, 15, 20 and 25 min 
intervals. The reactions were terminated by addition of equal volumes of a solution 
containing methanol and acetic acid at a 100:1 ratio. The samples were centrifuged at 
3,500 g for 20 min at 4 C and the supernatants were analyzed by reversed phase 
HPLC. The co–elution studies included a 25 min sample incubate that was spiked 
with a low concentration of an authentic standard (0.2–1 μM) of the putative 
metabolite.  
 
2.4 HPLC analysis 
The methodology has been described in detail in previous publications 
(Androutsopoulos et al., 2009a, Androutsopoulos et al., 2008). A Luna C18 4.6 x 150 
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mm 5 µ column was used with a mobile phase that contained solvents A and B. 
Solvent A comprised 1% acetonitrile and 0.5% acetic acid in H2O and solvent B 4% 
acetonitrile and 0.5% acetic acid in CH3OH. The following gradient was used: 60% 
solvent A and 40% solvent B at time=0 min and 10% solvent A and 90% solvent B at 
time=10 min. The final conditions were maintained for 1 min and the composition of 
the solvents was adjusted to the initial conditions with 8 min remaining for column 
equilibration after each run. The detection of the flavonoid concentration was was 
monitored using a Waters Series 200 UV detector (Waters, Hertfordshire, UK). 
Luteolin, 6 OH luteolin, kaempferol and quercetin were detected at 360 nm, whereas 
apigenin and scutellarein were detected at 350 nm. The concentration of the 
flavonoids was estimated by a calibration curve covering the concentration range of 
0.05–10 M for each compound. The assay was carried out at 37 C and the flow rate 
was 1 ml/min. The average recoveries for apigenin, luteolin, scutellarein, 6 OH 
luteolin, kaempferol and quercetin were estimated at 95, 91, 93, 87, 84 and 81%, 
respectively.  
 
2.5 Kinetics of 6 OH luteolin formation 
CYP1B1 recombinant microsomes (10 pmol/ml) were incubated with a concentration 
range of luteolin namely, 0.03-10 μM (10, 7, 5, 3, 2, 1, 0.5, 0.25, 0.125, 0.0625, 0.03 
μM) for 10 min. The optimum CYP1B1 concentration for linearity of product 
formation was estimated at 5 pmol/ml. The concentrations of 6 OH luteolin were 
estimated by a calibration curve covering the range 0.01 to 10 μM. Apparent Km and 
Vmax values were calculated using Graph Pad Prism (version 4.03). Intrinsic 
clearance (Cl) was calculated from the ratio Vmax/Km.    
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2.6 MTT assay  
MCF7, MDA–MB–468 and MCF10A cells (1 x 10
4
 cells/ml) were seeded in 96-well 
plates and the antiproliferative effect of the flavonoids was assayed as described 
previously (Androutsopoulos et al., 2008). Inhibition experiments were conducted in 
the presence of 0.5-1 μM α-napthoflavone and/or acacetin.  
 
2.7 Western blotting  
MCF7, MDA–MB–468 and MCF10A cells were cultured in T25 flasks at a density of 
5×10
5
 cells/ml. Following medium withdrawal and washing of the cells with PBS, the 
cells were lysed with 100 μl of lysis buffer that contained protease inhibitor cocktail 
and DL-dithiothreitol (DTT, 1 mM). The cells were sonicated on ice for 5 min and 
centrifuged at 13,000 rpm at 4 °C for 15 min. The protein concentration required for 
the experiment was adjusted to 0.7 mg/ml for each sample, and the protein extract was 
mixed with sample buffer that contained 5% mercaptoethanol at a 1:1 ratio. The 
samples were heated at 100 °C for 5 min and then loaded on an acrylamide gel 
containing 10% acrylamide for the resolving gel and 5% acrylamide for the stacking 
gel. Electrophoresis was carried out for 1 h at 120 V and the proteins were transferred 
by wet blotting to a PVDF membrane. The membrane was incubated in 10% 
milk/0.05% TBST at room temperature for 1 h by continuous shaking. The primary 
antibodies against CYP1B1 and β-actin were added to the membrane at 1:500 and 1: 
3,000 dilutions, respectively at 4 °C overnight. The membrane was subsequently 
washed three times with 0.05% TBST and incubated with the secondary antibody 
against HRP diluted in 1% milk/0.05% TBST at room temperature for 1.5 h. The 
membrane was finally exposed to ECL reagents, and the expression profile of the 
proteins was developed on film.  
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2.8 Molecular modeling 
For the docking procedure, the crystal structures of CYP1A1 (pdb code: 4I8V)(Walsh 
et al., 2013), CYP1B1 (pdb code: 3PM0)(Wang et al., 2011) and CYP1A2 (pdb code: 
2HI4)(Sansen et al. 2007) were obtained from the RSCB protein data bank. The 
enzymes were energy minimized using the conjugate gradient algorithm in the 
CHARMm forcefield for 500 steps to remove any conformational strain. The 
AutoDockTools program (Morris et al., 2009) was used to prepare the corresponding 
PDBQT-protein file, which included partial charges and solvation parameters for all 
the atoms. For all three enzymes, the heme Fe (II) ion formal charge was set to +2. 
The compounds were flexibly docked into the binding sites of each CYP1 using 
AutoDock Vina (Trott et al., 2010). The proteins were held rigid during the docking 
process, while the ligands were allowed to be flexible. Docking simulations in both 
cases were performed using a grid box with dimensions of 23x23x23 Å, a search 
space of 10 binding modes and the exhaustiveness parameter of 10.  
  
2.9 Statistical analysis 
The data were presented as the mean of at least three independent measurements and 
were analyzed by the paired and unpaired t-tests using GraphPadPrism. Error bars 
represent mean ± STDEV for at least n=3 determinations. 
 
3. Results 
3.1 CYP1 enzymes metabolize hydroxylated flavonoids 
Previous studies have demonstrated that CYP1 enzymes can demethylate mono–
methoxylated and/or poly–methoxylated flavonoids to their corresponding 
hydroxylated derivatives (Androutsopoulos et al., 2008, Androutsopoulos et al., 
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2009a, Androutsopoulos et al., 2009b, Androutsopoulos et al., 2009c). In the present 
study, the hypothesis that this metabolic pattern occurs in hydroxylated flavonoids 
was examined. CYP1 enzymes metabolized the hydroxylated flavonoids apigenin, 
and kaempferol and CYP1B1 metabolized the flavonoid luteolin over a 25 min 
incubation period compared with control microsomes containing empty vector, 
whereas quercetin metabolism by CYP1 enzymes did not yield any conversion 
products (Fig. 1, data not shown). The flavonoids apigenin and kaempferol that 
contained a single hydroxyl group on the B ring were more extensively metabolized 
by CYP1 enzymes compared with the flavonoid luteolin that contained 2 hydroxyl 
groups on the B ring (Fig. 1). CYP1A1 and CYP1A2 metabolized markedly apigenin 
and kaempferol compared with CYP1B1, whereas CYP1B1 was the sole catalyst of 
luteolin metabolism by CYP1 enzymes (Fig. 1). Notably, the concentration of 
apigenin was decreased from 8.8±0.3 μM to 5.8±0.2 μM following metabolism by 
CYP1A1, whereas CYP1B1 reduced the concentration of luteolin from 9.5±0.2 μM to 
7.4±0.5 μM (Fig. 1) over a 25 min incubation period.  
 
3.2 CYP1 enzymes catalyze hydroxylation reactions at the 3ʹ position of the B ring 
and the 6 position of the A ring of flavonoids 
Co–elution experiments were carried out with authentic standards corresponding to 
the putative CYP1–hydroxylated metabolites. Apigenin metabolism by CYP1A1 
yielded one major and one minor metabolite that were identified as luteolin and 
scutellarein (6 OH apigenin), respectively (Fig. 2A). The same metabolites were 
present by CYP1B1 and CYP1A2 metabolism of apigenin (Fig. 2A, data not shown). 
In contrast to CYP1A1, CYP1B1 yielded higher and lower amounts of scutellarein 
and luteolin, respectively (Fig. 2A). The metabolism of luteolin by CYP1A1 and  
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Figure 1. Cytochrome P450 CYP1–mediated metabolism of hydroxylated flavonoids. Recombinant 
CYP1 enzymes were incubated with hydroxylated flavonoids (10 μM) and samples were collected at 0, 
5, 10, 15, 20 and 25 min time intervals as described in Material and Methods. The experiments were 
conducted at least 3 times and error bars indicate STDEV of the mean. * indicate significant 
differences for the time points 10, 15 and 20 min of CYP1B1 samples compared to control samples 
(P<0.05). 
 
CYP1A2 did not yield any metabolites, whereas only one metabolite was present 
following CYP1B1 incubation with luteolin (Fig. 2B,C). The retention time of the 
authentic standard of the compound 5,7,3ʹ,4ʹ,5ʹ pentahydroxy flavone did not match 
the retention time of the CYP1B1 metabolite of luteolin, indicating that CYP1B1 does 
not hydroxylate luteolin at the 5ʹ position of the B ring (Fig. 2B,C). This metabolite 
was identified as 6–OH luteolin (Fig. 2B,C). The metabolism of kaempferol by CYP1 
enzymes yielded one metabolite that was identified as quercetin (Fig. 2D). The extent 
of metabolism followed the order CYP1A1>CYP1A2>CYP1B1 (Fig. 2D). In 
addition, an analysis of the metabolic turnover of the conversion products of the 
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Figure 2. HPLC analysis of hydroxylated flavonoids following incubation with CYP1 enzymes. (A) The 
metabolism of apigenin (10 μM) by CYP1 enzymes. Retention time of apigenin, luteolin, scutellarein 
and 6 OH luteolin authentic standards and of apigenin CYP1A1 and CYP1B1 incubates, as separated 
by the HPLC methodology used in the study. (B) The metabolism of luteolin (10 μM) by CYP1 enzymes. 
Retention time of luteolin, 6 OH luteolin and 5,7,3ʹ,4ʹ,5ʹ pentahydroxy flavone authentic standards and 
of luteolin CYP1A1, CYP1B1 and CYP1A2 incubates, as separated by the HPLC methodology used in 
the study. (C) Identification of 6 OH luteolin as the CYP1B1 metabolite of luteolin. The metabolic 
profile of a CYP1B1 incubate of luteolin (2 μM) was compared with the authentic standards 6 OH 
luteolin and 5,7,3ʹ,4ʹ,5ʹ pentahydroxy flavone in terms of retention time. (D) The metabolism of 
kaempferol (10 μM) by CYP1 enzymes. Retention time of kaempferol and quercetin as demonstrated by 
CYP1A1, CYP1B1 and CYP1A2 incubates, based on the HPLC methodology used in the study. 
 
CYP1–mediated metabolism of hydroxylated flavonoids was conducted. The highest 
amount of metabolite was formed by the CYP1A1–mediated conversion of apigenin 
to luteolin, followed by the formation of 6 OH luteolin by CYP1B1 and the formation 
of scutellarein from apigenin by CYP1B1 (Fig. 3A,B). The catalysis of kaempferol to 
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quercetin resulted in lesser amounts of product formation with regard to CYP1A1 and 
CYP1A2 compared with the corresponding CYP1–catalyzed metabolism of apigenin 
(Fig. 3B). 
    
3.3 The cytotoxicity of the hydxroxylated metabolites of CYP1 enzymes is increased 
compared to their corresponding parent compounds in breast cancer cell lines 
The CYP1 expressing cell lines MDA–MB–468 and MCF7 have been previously 
employed in order to assess the metabolism and further antiproliferative activity of 
dietary flavonoids (Androutsopoulos et al., 2008; Androutsopoulos et al., 2009a). In 
the present study the expression of CYP1B1 was further confirmed in the 
aforementioned cell lines by Western immunoblotting. Higher levels of CYP1B1 
expression were noted in MDA–MB–468 compared with MCF7 cells, whereas in 
MCF10A cell the expression of this enzyme was negligible (Fig. 4A). The expression 
of CYP1B1 in MCF7 cells was increased following induction of the cells for 24 h 
with 10 nM of the potent CYP1 inducer TCDD (tetrachloro-dibenzo-p-dioxin) (Fig. 
4A). 
The compounds apigenin, luteolin, scutellarein and 6OH luteolin exhibited higher 
antiproliferative activity in MDA–MB–468 compared with MCF10A cells in terms of 
IC50 values (Fig. 4B). Luteolin was the most potent compound in MDA–MB–468 
cells (IC50 = 2±0.3 μM), followed by 6OH luteolin, scutellarein and apigenin (Fig. 
4B). In MCF10A cells, 6OH luteolin was the most active compound with an IC50 of 
approximately 30 μM (Fig. 4B). In MCF7 cells, 6OH luteolin retained the maximun 
potency of growth inhibition followed by scutellarein, luteolin and apigenin (Fig. 4E). 






Figure 3. CYP1-mediated formation of flavonoid metabolites. A. The formation of scutellarein and 
luteolin by the CYP1–mediated metabolism of apigenin. Apigenin (10 μM) was incubated with 
recombinant CYP1 enzymes and the formation of the metabolites scutellarein and luteolin was detected 
by HPLC, as described in the materials and methods section. B. The formation of quercetin from 
kaempferol (10 μM) was catalyzed by all 3 CYP1 enzymes, whereas the formation of 6 OH luteolin 
from luteolin (10 μM) only by CYP1B1. Error bars indicate STDEV of the mean for n=3 experiments. 
 
 
luteolin was slightly increased (26.2±0.5 μM vs. 29.7±1.5μM and 22±0.36 μM vs. 
24±0.31 μM, P<0.05), whereas the IC50 values of the remaining compounds were 
unaffected (Fig. 4E). Similar findings were observed for the flavonols quercetin and 
kaempferol with regard to inhibition of MCF7 cell proliferation (data not shown). The 
parent compound kaempferol was less active than the metabolite quercetin in MDA–
MB–468 and MCF10A cells (Fig. 4D). Quercetin exhibited the lowest IC50 from the 
2 flavonols examined in MDA–MB–468 cells (Fig. 4D, 13.7±0.8 μM). 
Luteolin exhibited the lowest IC50 in MDA–MB–468 cells and yielded one 
metabolite that was produced solely by the enzyme CYP1B1. In order to test whether 
CYP1B1 metabolism was selective for luteolin in MDA–MB–468 cells in vitro, the 
cytotoxicity of this compound was estimated in the presence of the CYP1 inhibitors 
acacetin and α–napthoflavone. The incubation of luteolin with 1 μM of CYP1 
inhibitors reversed the IC50 noted in MDA–MB–468 cells (2±0.3 μM) to 15±2.3 μM 
(Fig. 4C), which indicated an approximate 7.5 fold selectivity of the MDA–MB–468 
cell line for luteolin (Fig. 4C). The IC50 noted in the presence of the CYP1 inhibitors 
for the MDA–MB–468 cells was comparable to that noted in MCF10A cells that were 
incubated with luteolin (30.4±5.4 μM) (Fig. 4C). It is important to note that the 
bioactivation of luteolin in MDA–MB–468 cells was attributed to CYP1B1 
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expression as demonstrated by HPLC analysis, western immunoblotting and CYP1 




Figure 4. The bioactivation of dietary flavonoids in the CYP1 expressing cell lines MDA–MB–468 and 
MCF7. A. The expression of CYP1B1 protein in MDA–MB–468, MCF10A and MCF7 cells. Protein 
extracts were obtained from the aforementioned cell lines and western blotting was conducted as 
described in Materials and Methods. MCF7 cells were pre–treated with 10 nM TCDD in order to 
induce the expression of CYP1B1. β–actin was used as a loading control for the samples derived from 
the human cell lines. Control microsomes (0.5 mg/ml) (Gentest, BD Biosciences) that were derived 
from recombinant insect cells with an empty vector were used as a negative control, whereas 
microsomes (Gentest, BD Biosciences) derived from recombinant insect cells expressing CYP1B1 (0.5 
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mg/ml) were used as a positive control. B. The IC50 of the flavones apigenin, luteolin, scutellarein and 
6 OH luteolin was estimated in MDA–MB–468 and MCF10A cell by MTT assay toxicity curves, as 
described in the Materials and Methods. * indicate significant differences for the IC50 values of 6 OH 
luteolin and luteolin in MCF10A cells (P<0.05). C. Luteolin is selectively bioactivated in MDA–MB–
468 breast cancer cells by CYP1B1. Luteolin was incubated at a concentration range covering 0.001-
100 μM for 96 hrs, in the presence (+ I) or absence of the CYP1B1/CYP1A1-inhibitors acacetin and/or 
α-napthoflavone (0.5–1 μM) and cell viability was measured using the MTT assay, as described in 
Materials and Methods. Error bars indicate STDEV of the mean for n = 3 experiments. D. The IC50 of 
the flavonols kaempferol and quercetin was estimated in MDA–MB–468 and MCF10A cell by MTT 
assay toxicity curves, as described in the Materials and Methods. E. The inhibition of cellular 
proliferation of MCF7 cells with and without pre–treatment with TCDD (10 nM) by the dietary 
flavones apigenin, luteolin, scutellarein and 6 OH luteolin. The IC50 for each compound was 
determined by MTT assay toxicity curves, as described in the Materials and Methods. * indicate 
significant differences for the IC50 values of apigenin and luteolin in non–induced MCF7 cells and 
MCF7 cells that were pre–induced with 10 nM of TCDD (P<0.05). 
 
 
3.4 CYP1B1 exhibits optimum metabolic turnover of luteolin 6 hydroxylation 
The kinetics of the formation of 6 OH luteolin from the CYP1B1-catalyzed 
metabolism of luteolin were investigated. The data indicated that the formation of 6 
OH luteolin followed Michaelis–Menten kinetics. The apparent Km and Vmax values 





, respectively (Figure 5). The intrinsic clearance 







 (Figure 5). Based on previous data published on the 












), the hydroxylation of luteolin at the 6 position was a more catalytically favorable  
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Figure 5. Michaelis–Menten kinetics of 6 OH luteolin formation by CYP1B1. Km, Vmax and intrinsic 
clearance values for the production of 6 OH luteolin by CYP1B1. The incubations were conducted as 
described in Materials and methods for 10 min using 10 pmol/min of CYP1B1 enzyme. The amount of 6 
OH luteolin was detected by UV absorption at 360 nm and converted into units of catalytic activity. 
Michaelis–Menten kinetic parameters were estimated using Graph Pad Prism (version 4.03). The error 
bars represent the mean SD for n = 3 independent determinations. 
 
 
reaction that required less substrate concentration in order to achieve the maximum 
formation of the product 6 OH luteolin (Androutsopoulos et al., 2009a). 
 
3.5 Molecular interactions of the flavonoids apigenin, luteolin and kaempferol with 
the heme group of CYP1 enzymes 
Apigenin, luteolin and kaempferol were docked to the heme binding site of CYP1B1 
and CYP1A1 in order to assess their preferable binding positions with regard to the 
heme group. The favorable orientations were evaluated using the dock scoring  
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Table 1. Docking scores of the two distinct poses of flavonoids (rings B and A towards the heme group) 




ring B A 
apigenin  -11.5 -10.9 
luteolin -11.2 -10.1 
kaempferol -11.5 -11.1 
   CYP1B1 
Flavonoid 
ring B A 
apigenin -11.7 -11.8 
luteolin -11 -11 
kaempferol -12 -11.9 
   CYP1A2 
Flavonoid 
ring B A 
apigenin -10.6 -10.5 
luteolin -10.1 -9.4 
kaempferol -10.5 -10.4 
 
 
function (Table 1). The residues of the enzyme CYP1A1 that were involved in the 
binding of the flavonoid molecules were mainly F123, N222, F224, L254 and F258. 
N222 appeared to bind with hydrogen bonds in all cases with regard to the orientation 
of apigenin and luteolin to the heme group. Docking of apigenin indicated a 
preferable orientation of the B ring (-11.5 kcal/mol) instead of the ring A (-10.9) 
towards the heme group with the formation of a hydrogen bond between N222 and 7 
–OH and 4ʹ –OH, respectively (Fig. 6A,B, Table 1). With regard to luteolin, the 
binding of ring B to the heme group revealed favorable docking scores (-11.2 
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kcal/mol) (Fig. 6C, Table 1) compared with the corresponding docking scores for ring 
A (-10.1 kcal/mol) (Fig. 6D, Table 1).  
The residues of the enzyme CYP1B1 that were involved in the binding of the 
flavonoids to the heme group were notably F134, N228, F231, N265, F268 and D333. 
Apigenin was predicted to bind to the heme group with similar docking scores with 
regard to the A (-11.8 kcal/mol) and B rings (-11.7 kcal/mol) (Fig. 7A, B).  In both 
cases, N228 was predicted to form a hydrogen bond with the carboxyl groups located 
in positions 4ʹ and 7 respectively. Similarly, both docking positions of luteolin 
exhibited the same binding scores (Table 1) for CYP1B1. For the A ring orientation 
towards heme, apart from the hydrogen bond between N228 and 4ʹ –OH, also 3ʹ –OH 
forms a hydrogen bond with the side chain of N265 (Fig. 7C). With regard to the B 
ring orientation, except from N228 and N265, the residue D333 was predicted to form 
a hydrogen bond with 3ʹ–OH, in addition to the interactions with the residues N228 
and N265 (Fig. 7D). However, the binding score was not increased probably due to 
additional non–favorable interactions.  
 
4. Discussion 
In the current study, evidence is presented regarding the CYP1–mediated metabolism 
of hydroxylated flavonoids. CYP1 enzymes were shown to catalyze hydroxylation 
reactions at the 3ʹ and 6 position of the B and A rings of hydroxylated flavonoids, 
respectively. With regard to B ring hydroxylation, CYP1A1 is more metabolically 
active compared with the remaining 2 CYP1 enzymes, whereas with regard to 
hydroxylation at the 6 position of the A ring CYP1B1 is the optimal catalyst. 
Furthermore, the addition of extra hydroxyl groups on the A and/or B rings of 
flavonoids enhances their antiproliferative activity with regard to breast cancer cells,  
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Figure 6. Human CYP1A1 active site models depicting the molecular interactions of the flavonoids 
apigenin and luteolin with the heme group of the cytochrome P450 enzyme. The substrates apigenin 
and luteolin (green and yellow sticks) and the main amino acids (cyan sticks) that comprise the active 
site cavity are shown. Oxygen and nitrogen atoms are colored red and blue, respectively. (A) Apigenin 
with the B ring orientation. (B) Apigenin with the A ring orientation. (C) Luteolin with the B ring 




as 6 OH luteolin was considerably more potent than apigenin (approximately 3.5–fold 
activation) in inhibiting proliferation of MCF7 and MDA–MB–468 cells. CYP1B1 is 
considered to play a significant role in the metabolic activation of luteolin in breast 
cancer MDAMB468 cells, as demonstrated by the IC50 of luteolin in the presence 
of the CYP1 inhibitors acacetin and/or αnapthoflavone. The hydroxylation of 
luteolin at the 6 position of the A ring is an important structural feature that 
determines the antiproliferative activity of luteolin in breast cancer cells. 
Dietary flavonoids have been considered the hallmark molecules for cancer 
prevention. Long term in depth research on the bioactivity of dietary flavonoids has 
been exhaustively conducted during the last 30 years. Although significant advances 
have been made with regard to their mechanism of action, a common model that links 
the core structure of flavones and flavonols with the degree of their antiproliferative 
action is yet to be established. This is notably due to the diversity of their mode of 
anticancer action. Certain flavonoids have been characterized as apoptosis inducers, 
whereas others as cell cycle inhibitors, cell signaling modulators and/or antioxidants 
(Priyadarsini et al., 2010; Bitis et al., 2010; Cheng et al., 2011; Curti et al., 2017; 
Seelinger et al., 2008). In the present study, a unifying model is presented where the 
inhibition of breast cancer cellular proliferation caused by structurally related 
flavonoids is dependent on their CYP1mediated metabolism. The data presented are 
in agreement with the previous studies conducted by our group regarding the 
bioactivation of the methoxylated flavonoids eupatorin, cirsiliol, diosmetin and 
genkwanin by CYP1 enzymes in breast cancer cells (Androutsopoulos et al., 2008; 
Androutsopoulos et al., 2009a; Androutsopoulos et al., 2009b; Androutsopoulos et al., 
2009c). It is important to note that the number of hydroxyl groups in the flavonoid 
structure of the metabolites enhanced the total antiproliferative activity compared with  
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Figure 7. Human CYP1B1 active site models depicting the molecular interactions of the flavonoids 
apigenin and luteolin with the heme group of the cytochrome P450 enzyme. The substrates apigenin 
and luteolin (green and yellow sticks) and the main amino acids (cyan sticks) that comprise the active 
site cavity are shown. Oxygen and nitrogen atoms are colored red and blue, respectively. (A) Apigenin 
with the A ring orientation. (B) Apigenin with the B ring orientation. (C) Luteolin with the A ring 




that noted for the parent compounds (Androutsopoulos et al., 2009c), which is in 
concordance with the results presented in the current study. For example, genkwanin 
(parent compound) was less active than apigenin (metabolite) and scutellarein 
(metabolite), whereas diosmetin (parent compound) was less active than luteolin 
(metabolite) (Androutsopoulos et al., 2009c; Androutsopoulos et al., 2009a; 
Androutsopoulos et al., 2009b). Similarly, the present study demonstrated that 
apigenin (parent compound) was less active than scutellarein (metabolite) and 
kaempferol (parent compound) than quercetin (metabolite) in inhibiting the 
proliferation of MDAMB468 and MCF7 cells. 
Although the chemopreventive function of the flavonoids apigenin, luteolin, 
kaempferol and quercetin has been extensively investigated, evidence regarding the 
anticancer activity of the flavonoids 6 OH luteolin and scutellarein is limited. This is 
possibly due to the limited knowledge concerning the relative abundance of these 
compounds in dietary products and food. It is well known that apigenin and luteolin, 
are the main constituents of parsley, celery, green peppers and chamomile, whereas 
kaempferol and quercetin are notably found in apples and onions. However, the 
sources of 6 OH luteolin and scutellarein that have been identified to date are mostly 
plant species that are used for traditional medicinal use and are absent from the daily 
diet (Uehara et al., 2015; Nalewajko-Sieliwoniuk et al., 2015; de Beer et al., 2011). 
The sole food source that has been reported for 6 OH luteolin and scutellarein is 
Mexican oregano (Lin et al., 2007). With regard to their biological activity, several 
reports have suggested antioxidant, antimutagenic and antiproliferative modes of 
action (de Oliveira et al., 2013; Peng et al., 2003; Gordo et al., 2012; Nagao et al., 
2002). It is important to note that luteolin was more potent than apigenin in HeLa 
cervical carcinoma and B16F10 melanoma cells, whereas 6 OH luteolin was more  
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Figure 8. Putative metabolic pathway indicating the bioactivation of luteolin and structurally related 
dietary flavonoids by CYP1B1 in cancer cells. The mechanism of action may be attributed to induction 
of cell cycle arrest and apoptosis by modulation of cell signaling, as previously reported 
(Androutsopoulos and Spandidos 2013; Zhang et al., 2009; Meng et al., 2017; Chen et al., 2017; 
Sonoki et al., 2017). 
 
 
potent than luteolin only in B16F10 cells (Nagao et al., 2002). This suggests that 
hydroxylation reactions at the A and B ring of flavones may partially enhance the 
antiproliferative activity of the parent compounds, which is in concordance with the 
present study.  
The interactions of dietary flavonoids with CYP1 enzymes have notably been 
investigated in terms of inhibition studies. The majority of the literature has explored 
the capacity of these compounds to inhibit CYP1 enzyme activity by direct and/or 
indirect assays (Schwarz et al., 2005; Schwarz et al., 2003; Takemura et al., 2010; 
Doodstdar et al., 2000; Ciolino et al., 1998; Ciolino et al., 1999; Zhai et al., 1998). 
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The metabolism of hydroxylated flavonoids has been investigated to a lesser extent. It 
was reported in an early study that the flavonols galangin (3ʹ,5,7 trihydroxyflavone) 
and kaempferide were both hydroxylated and demethylated at the 4ʹ position of the B 
ring, respectively in order to yield the metabolite kaempferol (Otake and Walle 2002). 
This type of bioconversion (galangin to kaempferol) has been shown to occur in vitro 
in Caco–2 cells that were pre–induced with TCDD (Hamada et al., 2010). In addition, 
the conversion of luteolin by apigenin has been demonstrated by Breinholt and 
colleagues only for human CYP1A2 (Breinholt et al. 2002). The present findings 
corroborate the aforementioned studies and highlight that aromatic hydroxylation 
reactions can be catalyzed by CYP1 enzymes to the pre–substituted B ring of dietary 
flavonoids. Hydroxyl groups can be added to the 4ʹ position of the unsubstituted ring 
of galangin to yield kaempferol, which in turn can be metabolized to quercetin. 
Similarly, hydroxylation at the 6 position of the A ring was demonstrated to occur for 
apigenin and luteolin in order to yield scutellarein and 6 OH luteolin, respectively. It 
is important to note that CYP1B1 is shown for the first time to play a significant role 
in the catalysis of these reactions, since earlier studies were notably focused on 
CYP1A1 and CYP1A2.  
In addition to metabolism studies, docking calculations depicted a general preference 
of the B ring orientation towards the heme group for CYP1A1, although this trend 
was not noted for CYP1B1 and/or CYP1A2 (with the exception of luteolin). 
Furthermore, the B ring orientation towards the heme group of CYP1A1 was favored 
compared with the A ring for the hydroxylation of apigenin, which was in agreement 
with the metabolism studies. With regard to CYP1B1, similar scores were noted for 
the docking of the A and B ring orientations of luteolin to the heme group, indicating 
no preference for a ring group towards hydroxylation, as demonstrated by the docking 
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calculations. It is important to note that the energy levels required for the docking of 
the A ring orientations of both apigenin and luteolin to the heme group of CYP1B1, 
were higher compared to those noted to the heme group of CYP1A1 (Table 1), which 
indicates that CYP1B1 favors the A ring orientation compared with CYP1A1. This 
finding is in agreement with the data derived from the metabolism studies that 
demonstrated favorable metabolism of apigenin and luteolin by CYP1B1 to the 6 
hydroxylated derivatives namely, scutellarein and 6 OH luteolin (A ring orientation) 
compared with CYP1A1 that demonstrated lesser or no metabolism at the 6 position 
of the A ring. Moreover, luteolin was not metabolized by CYP1A1 and CYP1A2 
indicating that it acts more as a inhibitor rather than a substrate for these enzymes.     
The bioactivation of luteolin in MDA–MB–468 cells was attributed to metabolism of 
this compound by CYP1B1, as in the presence of the CYP1B1/CYP1A1 inhibitor α-
napthoflavone and/or acacetin, the inhibition of cellular proliferation by luteolin was 
lessened. A similar trend has been previously demonstrated for the flavonoids 
genkwanin and eupatorin in our earlier reports (Androutsopoulos et al., 2008; 
Androutsopoulos et al., 2009c). These compounds exhibited IC50s for MDA–MB–
468 cells of 1.6 and 0.5 μM, respectively. The potent inhibition of cellular 
proliferation was reversed by cotreatment with the CYP1B1 inhibitor acacetin. The 
IC50 values in the presence of acacetin were increased to 15 μM for eupatorin and to 
12.5 μM for genkwanin (Androutsopoulos et al., 2008; Androutsopoulos et al., 
2009c). Luteolin exhibited a similar activation threshold (approximately 7.5–fold 
activation in MDA–MB–468 cells). However, although eupatorin and genkwanin 
were metabolized by all three CYP1 enzymes, luteolin was solely metabolized by 
CYP1B1, indicating that CYP1B1 was notably responsible for the bioactivation of 
this compound in MDA–MB–468 cells. CYP1B1 has previously been reported as a 
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putative cancer therapeutic target due to the selective overexpression of this enzyme 
in tumor cells (McFadyen et al., 1999; McFadyen et al., 2004; Murray et al., 1997; 
Androutsopoulos et al., 2013; Spyrou et al., 2014). However, with regard to the 
detection of CYP1B1 enzymatic activity in human tumors, a paucity of studies has 
been conducted and the evidence presented is limited in order to address the accurate 
determination of CYP1B1 activity levels in tumors (McFadyen et al., 2004; 
Androutsopoulos et al., 2013; Spyrou et al., 2014). Despite these inconsistencies, the 
present study reveals that luteolin is an optimum substrate for CYP1B1, as 
demonstrated by its low Km and high intrinscic clearance. Consequently, the 
formation of 6 OH luteolin in breast cancer cells will theoretically require a very 
small amount of initial substrate concentration that can be achieved by a minimum 
CYP1B1 activity level. Thus, it could be deduced that luteolin could exhibit 
significant therapeutic applications in human breast cancer via the selective 
metabolism to 6 OH luteolin by CYP1B1.  
It is important to note that the bioactivation of dietary flavonoids in MDA–MB–468 
and MCF7 breast cancer cells cannot be solely attributed to the production of one 
single CYP1–metabolite that corresponds to each parent compound (i.e. luteolin from 
apigenin, scutellarein from apigenin). It is more likely that a combination effect of the 
CYP1–flavonoid metabolites with their corresponding parent compounds occurs. For 
example, the bioactivation of apigenin is possibly attributed to the concomitant 
antiproliferative action of apigenin, luteolin and scutellarein. A similar finding has 
been previously reported for the conversion of luteolin from diosmetin by CYP1A1 in 
liver cancer HepG2 cells (Androutsopoulos and Spandidos 2013). This study 
indicated a synergistic mode of action between the two compounds with regard to the 
inhibition of HepG2 cell proliferation (Androutsopoulos and Spandidos 2013). 
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Furthermore, the mechanism of action of the CYP1–mediated metabolites has been 
attributed to induction of apoptosis, activation of cell signaling proteins, induction of 
cell cycle inhibitors and inhibition of topoisomerase–I catalyzed DNA relegation 
(Zhang et al. 2009; Kandaswami et al., 1999; Androutsopoulos and Spandidos 2013; 
Boege et al., 1996). It is likely that these biological processes occur in breast cancer 
cells that express active CYP1B1 (Figure 6).   
In conclusion, the present study investigated the anticancer effects of hydroxylated 
flavones and flavonols with regard to CYP1–mediated metabolism and inhibition of 
cellular proliferation of human breast cancer cells. The data demonstrate that 
hydroxylation of dietary flavonoids by CYP1 enzymes can enhance their 
antiproliferative activity in human breast cancer cells. The overall effect is possibly 
attributed to the combined action of the parent compound and the corresponding 
metabolites. Moreover, the flavonoid luteolin is characterized as a selective CYP1B1–
activated prodrug that originates from dietary sources and can exert significant 
therapeutic effects in breast cancer cells that express active CYP1B1. Current research 
is in progress to examine the in vivo therapeutic effects of luteolin and to design semi-
synthetic flavonoids that aim to enhance markedly (up to 100-fold) the cytotoxic 
action of their corresponding metabolites thus providing more evidence on the use of 
cytochrome P450s in cancer therapy.           
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